HUA MEDICINE-B (02552), an innovative pharmaceutical company focused on diabetes treatment, saw its stock price soar by 5.02% in Friday's trading session. This surge comes on the heels of the company's impressive interim results for the first half of 2025, which showcase significant financial and operational improvements.

The company reported a remarkable 112% year-on-year increase in total revenue, reaching approximately RMB 217.4 million. HUA MEDICINE-B achieved its first semi-annual profitability, with a pre-tax profit of RMB 1.1839 billion, largely due to the recognition of deferred revenue from the termination of an agreement with Bayer. The company's flagship product, HTOLYSE®, demonstrated strong market performance with sales volume increasing by 108% year-on-year to 1.764 million boxes.

Investors appear optimistic about HUA MEDICINE-B's future prospects, including its expanding R&D pipeline for combination therapies, progress in international markets, and the development of second-generation GKA. The company's strategic focus on "diabetes and metabolic diseases" and its efforts to optimize cost structure have positioned it well for continued growth in the competitive biomedical sector.